Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US

7 references·7 citing·37 second hop

FromToDepth

this work references cited by second hop

References

2016Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 20156,217 cited
1997The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials2,052 cited
2016Cost-Effectiveness in Health and Medicine1,550 cited
2005US Valuation of the EQ-5D Health States1,274 cited
2016Cost–effectiveness thresholds: pros and cons789 cited
2013Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data541 cited
2017Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States142 cited

Cited by

2021Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer93 cited
2019Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US79 cited
2019Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer75 cited
2019Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States74 cited
2019Cost–Effectiveness of Pembrolizumab Versus Chemotherapy as First-Line Treatment in PD-L1-Positive Advanced Non-Small-Cell Lung Cancer in the USA

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

68 cited

2020Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer62 cited

2020Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review59 cited